CoChat

Reduced nicotinamide mononucleotide is a new and potent NAD + precursor in mammalian cells and mice

Open access
Zapata‐Pérez, Rubén, Tammaro, Alessandra, Schomakers, Bauke V., Scantlebery, Angelique M. L., Denis, Simone, Elfrink, Hyung L., Giroud‐Gerbetant, Judith, Cantó, Carles, López‐Leonardo, Carmen, McIntyre, Rebecca L., van Weeghel, Michel, Sánchez‐Ferrer, Álvaro, Houtkooper, Riekelt H. · 2021 · The FASEB Journal
Cited by 72

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Nicotinamide adenine dinucleotide (NAD + ) homeostasis is constantly compromised due to degradation by NAD + ‐dependent enzymes. NAD + replenishment by supplementation with the NAD + precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) can alleviate this imbalance. However, NMN and NR are limited by their mild effect on the cellular NAD + pool and the need of high doses. Here, we report a synthesis method of a reduced form of NMN (NMNH), and identify this molecule as a new NAD + precursor for the first time. We show that NMNH increases NAD + levels to a much higher extent and faster than NMN or NR, and that it is metabolized through a different, NRK and NAMPT‐independent, pathway. We also demonstrate that NMNH reduces damage and accelerates repair in renal tubular epithelial cells upon hypoxia/reoxygenation injury. Finally, we find that NMNH administration in mice causes a rapid and sustained NAD + surge in whole blood, which is accompanied by increased NAD + levels in liver, kidney, muscle, brain, brown adipose tissue, and heart, but not in white adipose tissue. Together, our data highlight NMNH as a new NAD + precursor with therapeutic potential for acute kidney injury, confirm the existence of a novel pathway for the recycling of reduced NAD + precursors and establish NMNH as a member of the new family of reduced NAD + precursors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1096/fj.202001826r

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 72

Metadata

Authors
Zapata‐Pérez, R., Tammaro, A., Schomakers, B. V., Scantlebery, A. M. L., Denis, S., Elfrink, H. L., Giroud‐Gerbetant, J., Cantó, C., López‐Leonardo, C., McIntyre, R. L., van Weeghel, M., Sánchez‐Ferrer, Á., & Houtkooper, R. H.
Venue
The FASEB Journal
Publisher
Wiley
Published
2021-03-16
Volume
35
Issue
4
Pages
e21456-e21456
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W3136425725
Cited by
72
References
29
FWCI
6.70
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reduced nicotinamide mononucleotide is a new and potent NAD + precursor in mammalian cells and mice. https://app.cochat.ai/papers/10.1096/fj.202001826r
The paper
Zapata‐Pérez, R., Tammaro, A., Schomakers, B. V., Scantlebery, A. M. L., Denis, S., Elfrink, H. L., Giroud‐Gerbetant, J., Cantó, C., López‐Leonardo, C., McIntyre, R. L., van Weeghel, M., Sánchez‐Ferrer, Á., & Houtkooper, R. H. (2021). Reduced nicotinamide mononucleotide is a new and potent NAD + precursor in mammalian cells and mice. The FASEB Journal. https://doi.org/10.1096/fj.202001826r

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.